HomeCompareFGEN vs O

FGEN vs O: Dividend Comparison 2026

FGEN yields 22.05% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGEN wins by $48.5K in total portfolio value
10 years
FGEN
FGEN
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full FGEN calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — FGEN vs O

📍 FGEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGENO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGEN + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGEN pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGEN
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, FGEN beats the other by $2,751.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGEN + O for your $10,000?

FGEN: 50%O: 50%
100% O50/50100% FGEN
Portfolio after 10yr
$58.5K
Annual income
$6,721.43/yr
Blended yield
11.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

FGEN
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$28.00
+208.7% upside vs current
Range: $28.00 — $28.00
Altman Z
-20.3
Piotroski
6/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGEN buys
0
O buys
0
No recent congressional trades found for FGEN or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGENO
Forward yield22.05%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$82.7K$34.2K
Annual income after 10y$8,340.12$5,102.74
Total dividends collected$49.4K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$28.00$64.00

Year-by-year: FGEN vs O ($10,000, DRIP)

YearFGEN PortfolioFGEN Income/yrO PortfolioO Income/yrGap
1← crossover$12,905$2,205.07$10,818$608.16+$2.1KFGEN
2$16,468$2,659.50$11,787$741.68+$4.7KFGEN
3$20,792$3,171.71$12,946$911.00+$7.8KFGEN
4$25,990$3,742.62$14,345$1,127.94+$11.6KFGEN
5$32,182$4,372.22$16,056$1,409.05+$16.1KFGEN
6$39,494$5,059.61$18,171$1,777.83+$21.3KFGEN
7$48,062$5,803.04$20,820$2,268.21+$27.2KFGEN
8$58,026$6,599.92$24,188$2,929.90+$33.8KFGEN
9$69,535$7,446.93$28,533$3,837.11+$41.0KFGEN
10$82,743$8,340.12$34,235$5,102.74+$48.5KFGEN

FGEN vs O: Complete Analysis 2026

FGENStock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Full FGEN Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this FGEN vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGEN vs SCHDFGEN vs JEPIFGEN vs KOFGEN vs MAINFGEN vs STAGFGEN vs ADCFGEN vs NNNFGEN vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.